Founded with a mission to address urgent needs in immune-driven critical and chronic illnesses, Endpoint Health focuses on delivering personalized therapies tailored to each patient’s biology. The company develops and commercializes therapeutics and therapy-guiding tests, aiming to ensure that every patient receives effective, individualized treatment. Their vision is a world where personalized treatment improves patient outcomes, particularly in the realm of precision immunology.
Endpoint Health has attracted notable investors and partners in the biopharma industry, contributing to its rapid growth and innovation. The company has made significant strides in developing precision-first therapeutics, challenging traditional molecule-first drug development models. By leveraging advanced clinical and data ecosystems, Endpoint Health is pioneering new approaches in precision medicine, significantly impacting the treatment landscape for immune-mediated diseases.
